KIT2014 is a novel inhaled peptide therapy being developed for respiratory diseases including chronic obstructive pulmonary disease (COPD), ...

PQQ and ergothioneine have drawn growing interest in beauty research, but published human skin data on oral PQQ remain scarce ...

The MEND-PNPO study has successfully enrolled 10 patients, meeting the Company's enrollment objective. Patients enrolled in ...

Two speakers at Optometry’s Meeting urged optometrists to get involved in clinical trials to provide their patients with the ...

The FDA has granted 510(k) clearance for an insulin titration algorithm that uses continuous glucose monitoring and insulin ...

Substantially all planned REO 033 clinical sites are now activated, with multiple patients currently on study Company expects to have sufficient Part A data to provide an interim clinical update by ...

Phase 3 trial data show significant scalp, eyelash, and eyebrow hair regrowth at 36 weeks in adolescents treated with oral baricitinib.

Tarcocimab, tabirafusp-ted were noninferior to aflibercept in DAYBREAK wet AMD trial; 54% on tarcocimab reached 24-week dosing.

Amgen’s phase 3 OASIZ 301 trial shows dazodalibep significantly improves systemic disease activity in adults with moderate to severe Sjögren disease at week 48.

The BANYAN Trial is evaluating intranasal foralumab in people living with amyotrophic lateral sclerosis (ALS). The study is sponsored by Tiziana Life Sciences and co-funded by the ALS Association ...

The FDA has approved Gazyva (obinutuzumab) to reduce relapse risk in adult and pediatric patients aged 2 years and older with idiopathic nephrotic syndrome.

Puma Biotechnology has launched the phase 2 ALISCA-Lung2 trial (PUMA-ALI-4202; NCT07465757) evaluating the investigational ...